Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > The Future Value of TLT.v

<< Previous

Bullboard Posts

Next >>

Comment by gebremeskelon Feb 06, 2024 5:26pm

259 Views

Post# 35866313

RE:The Future Value of TLT.v

Could be. But keep in mind that hasn't even been tried in humans yet. Our value right now is in a superior second line treatment for high grade bladder cancer that has excellent prospects for approval within the next few years.

Tarbaby wrote: IMO the future value of Theralase is in their patents for XPDT and Immunotherapy.
And their targetting drug Rutherrin.

It can target and destroy deep seated tumours but avoid healthy cells.

Xrays or radiation of low intensity will trigger the absorbed Rutherrin in cancer cells to react and kill or damage the cells. Damaged cancer cells then alert an immune response which finishes the job anywhere in the body.